Phibro Animal Health (PAHC)
Market Price (7/25/2026): $0 | Market Cap: $-Sector: Health Care | Industry: Pharmaceuticals
Phibro Animal Health (PAHC)
Market Price (7/25/2026): $0Market Cap: $-Sector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.3%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.0% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% Megatrend and thematic driversMegatrends include Health & Wellness Trends, Biotechnology & Genomics, and Precision Medicine. Themes include Nutritional Supplements, Show more. | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 51% Key risksPAHC key risks include [1] operational, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.3%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.0% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40% |
| Megatrend and thematic driversMegatrends include Health & Wellness Trends, Biotechnology & Genomics, and Precision Medicine. Themes include Nutritional Supplements, Show more. |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 51% |
| Key risksPAHC key risks include [1] operational, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/1/2026
Phibro Animal Health (PAHC) stock has lost about 40% since 3/31/2026 because of the following key factors:
1. Regulatory Headwinds in Brazil Overshadow Strong Q3 Fiscal 2026 Performance.
Despite reporting strong financial results for its third fiscal quarter ended March 31, 2026, Phibro Animal Health's stock experienced a significant decline due to new regulatory changes in Brazil. The company announced net sales increased 10% to $383.5 million and adjusted EBITDA rose 11% to $60.8 million, exceeding analyst expectations for both metrics. However, Brazil implemented a new framework removing "growth promotion and performance indications for certain antimicrobials," including key products like virginiamycin and bacitracin, impacting Phibro's Animal Health segment, particularly medicated feed additives (MFAs). This news, released alongside the earnings on May 7, 2026, triggered a sharp sell-off, with the stock falling more than 24% in premarket trading that day, as investor concerns about these "regulatory and geopolitical risks" outweighed the positive quarterly results.
2. Analyst Downgrades and Price Target Cuts Reflect Increased Caution.
Following the Q3 fiscal 2026 earnings report and the regulatory concerns, Wall Street analysts revised their outlook for Phibro Animal Health, contributing to the stock's downturn. Notably, Citigroup cut its price target for PAHC from $62 to $44 in mid-May 2026, while maintaining a Neutral rating on the stock. This adjustment was attributed to "regulatory pressures affecting the industry as well as valuation compression across comparable companies," indicating a more cautious stance on the company's future prospects. The consensus analyst rating for PAHC shifted to "Hold," with some forecasts predicting continued negative price trends.
Show more
Phibro Animal Health (PAHC) stock has lost about 40% since 3/31/2026 because of the following key factors:
1. Regulatory Headwinds in Brazil Overshadow Strong Q3 Fiscal 2026 Performance.
Despite reporting strong financial results for its third fiscal quarter ended March 31, 2026, Phibro Animal Health's stock experienced a significant decline due to new regulatory changes in Brazil. The company announced net sales increased 10% to $383.5 million and adjusted EBITDA rose 11% to $60.8 million, exceeding analyst expectations for both metrics. However, Brazil implemented a new framework removing "growth promotion and performance indications for certain antimicrobials," including key products like virginiamycin and bacitracin, impacting Phibro's Animal Health segment, particularly medicated feed additives (MFAs). This news, released alongside the earnings on May 7, 2026, triggered a sharp sell-off, with the stock falling more than 24% in premarket trading that day, as investor concerns about these "regulatory and geopolitical risks" outweighed the positive quarterly results.
2. Analyst Downgrades and Price Target Cuts Reflect Increased Caution.
Following the Q3 fiscal 2026 earnings report and the regulatory concerns, Wall Street analysts revised their outlook for Phibro Animal Health, contributing to the stock's downturn. Notably, Citigroup cut its price target for PAHC from $62 to $44 in mid-May 2026, while maintaining a Neutral rating on the stock. This adjustment was attributed to "regulatory pressures affecting the industry as well as valuation compression across comparable companies," indicating a more cautious stance on the company's future prospects. The consensus analyst rating for PAHC shifted to "Hold," with some forecasts predicting continued negative price trends.
Show more
Updated on 7/1/2026
Phibro Animal Health (PAHC) stock has lost about 40% since 3/31/2026 because of the following key factors:
1. Regulatory Headwinds in Brazil Overshadow Strong Q3 Fiscal 2026 Performance.
Despite reporting strong financial results for its third fiscal quarter ended March 31, 2026, Phibro Animal Health's stock experienced a significant decline due to new regulatory changes in Brazil. The company announced net sales increased 10% to $383.5 million and adjusted EBITDA rose 11% to $60.8 million, exceeding analyst expectations for both metrics. However, Brazil implemented a new framework removing "growth promotion and performance indications for certain antimicrobials," including key products like virginiamycin and bacitracin, impacting Phibro's Animal Health segment, particularly medicated feed additives (MFAs). This news, released alongside the earnings on May 7, 2026, triggered a sharp sell-off, with the stock falling more than 24% in premarket trading that day, as investor concerns about these "regulatory and geopolitical risks" outweighed the positive quarterly results.
2. Analyst Downgrades and Price Target Cuts Reflect Increased Caution.
Following the Q3 fiscal 2026 earnings report and the regulatory concerns, Wall Street analysts revised their outlook for Phibro Animal Health, contributing to the stock's downturn. Notably, Citigroup cut its price target for PAHC from $62 to $44 in mid-May 2026, while maintaining a Neutral rating on the stock. This adjustment was attributed to "regulatory pressures affecting the industry as well as valuation compression across comparable companies," indicating a more cautious stance on the company's future prospects. The consensus analyst rating for PAHC shifted to "Hold," with some forecasts predicting continued negative price trends.
3. Removal from Russell Indices Impacts Institutional Ownership and Liquidity.
Effective July 2, 2026, Phibro Animal Health was removed from several Russell indices, including the Russell Microcap and Russell 3000E groupings. This technical event can lead to a reduction in demand for the stock from index-tracking funds, as these funds are mandated to adjust their portfolios to align with index compositions. The removal can negatively affect the stock's liquidity and potentially exert further selling pressure, contributing to its overall decline. Phibro's share price saw a 90-day decline of 42.18% as of July 2, 2026.
Show less
Phibro Animal Health (PAHC) stock has lost about 40% since 3/31/2026 because of the following key factors:
1. Regulatory Headwinds in Brazil Overshadow Strong Q3 Fiscal 2026 Performance.
Despite reporting strong financial results for its third fiscal quarter ended March 31, 2026, Phibro Animal Health's stock experienced a significant decline due to new regulatory changes in Brazil. The company announced net sales increased 10% to $383.5 million and adjusted EBITDA rose 11% to $60.8 million, exceeding analyst expectations for both metrics. However, Brazil implemented a new framework removing "growth promotion and performance indications for certain antimicrobials," including key products like virginiamycin and bacitracin, impacting Phibro's Animal Health segment, particularly medicated feed additives (MFAs). This news, released alongside the earnings on May 7, 2026, triggered a sharp sell-off, with the stock falling more than 24% in premarket trading that day, as investor concerns about these "regulatory and geopolitical risks" outweighed the positive quarterly results.
2. Analyst Downgrades and Price Target Cuts Reflect Increased Caution.
Following the Q3 fiscal 2026 earnings report and the regulatory concerns, Wall Street analysts revised their outlook for Phibro Animal Health, contributing to the stock's downturn. Notably, Citigroup cut its price target for PAHC from $62 to $44 in mid-May 2026, while maintaining a Neutral rating on the stock. This adjustment was attributed to "regulatory pressures affecting the industry as well as valuation compression across comparable companies," indicating a more cautious stance on the company's future prospects. The consensus analyst rating for PAHC shifted to "Hold," with some forecasts predicting continued negative price trends.
3. Removal from Russell Indices Impacts Institutional Ownership and Liquidity.
Effective July 2, 2026, Phibro Animal Health was removed from several Russell indices, including the Russell Microcap and Russell 3000E groupings. This technical event can lead to a reduction in demand for the stock from index-tracking funds, as these funds are mandated to adjust their portfolios to align with index compositions. The removal can negatively affect the stock's liquidity and potentially exert further selling pressure, contributing to its overall decline. Phibro's share price saw a 90-day decline of 42.18% as of July 2, 2026.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -38.2% change in PAHC stock from 3/31/2026 to 7/24/2026 was primarily driven by a -40.2% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 7242026 | Change |
|---|---|---|---|
| Stock Price ($) | 55.08 | 34.03 | -38.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,464 | 1,500 | 2.4% |
| Net Income Margin (%) | 6.3% | 6.3% | 1.0% |
| P/E Multiple | 24.2 | 14.5 | -40.2% |
| Shares Outstanding (Mil) | 41 | 41 | 0.0% |
| Cumulative Contribution | -38.2% |
Market Drivers
3/31/2026 to 7/24/2026| Return | Correlation | |
|---|---|---|
| PAHC | -38.2% | |
| Market (SPY) | 13.6% | 23.4% |
| Sector (XLV) | 10.9% | 31.8% |
Fundamental Drivers
The -8.3% change in PAHC stock from 12/31/2025 to 7/24/2026 was primarily driven by a -34.7% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 7242026 | Change |
|---|---|---|---|
| Stock Price ($) | 37.12 | 34.03 | -8.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,400 | 1,500 | 7.2% |
| Net Income Margin (%) | 4.8% | 6.3% | 31.0% |
| P/E Multiple | 22.2 | 14.5 | -34.7% |
| Shares Outstanding (Mil) | 41 | 41 | 0.0% |
| Cumulative Contribution | -8.3% |
Market Drivers
12/31/2025 to 7/24/2026| Return | Correlation | |
|---|---|---|
| PAHC | -8.3% | |
| Market (SPY) | 8.7% | 21.5% |
| Sector (XLV) | 5.5% | 26.5% |
Fundamental Drivers
The 34.9% change in PAHC stock from 6/30/2025 to 7/24/2026 was primarily driven by a 137.8% change in the company's Net Income Margin (%).| (LTM values as of) | 6302025 | 7242026 | Change |
|---|---|---|---|
| Stock Price ($) | 25.22 | 34.03 | 34.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,191 | 1,500 | 26.0% |
| Net Income Margin (%) | 2.7% | 6.3% | 137.8% |
| P/E Multiple | 32.1 | 14.5 | -54.9% |
| Shares Outstanding (Mil) | 41 | 41 | -0.1% |
| Cumulative Contribution | 34.9% |
Market Drivers
6/30/2025 to 7/24/2026| Return | Correlation | |
|---|---|---|
| PAHC | 34.9% | |
| Market (SPY) | 20.6% | 23.2% |
| Sector (XLV) | 22.2% | 26.2% |
Fundamental Drivers
The 166.3% change in PAHC stock from 6/30/2023 to 7/24/2026 was primarily driven by a 117.2% change in the company's Net Income Margin (%).| (LTM values as of) | 6302023 | 7242026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.78 | 34.03 | 166.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 978 | 1,500 | 53.4% |
| Net Income Margin (%) | 2.9% | 6.3% | 117.2% |
| P/E Multiple | 18.1 | 14.5 | -20.0% |
| Shares Outstanding (Mil) | 41 | 41 | -0.1% |
| Cumulative Contribution | 166.3% |
Market Drivers
6/30/2023 to 7/24/2026| Return | Correlation | |
|---|---|---|
| PAHC | 166.3% | |
| Market (SPY) | 72.6% | 30.9% |
| Sector (XLV) | 28.2% | 28.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PAHC Return | 7% | -32% | -10% | 86% | 81% | -8% | 101% |
| Peers Return | 18% | -30% | 25% | -21% | 19% | 3% | -1% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| PAHC Win Rate | 75% | 42% | 50% | 75% | 67% | 71% | |
| Peers Win Rate | 55% | 37% | 55% | 42% | 43% | 54% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| PAHC Max Drawdown | -36% | -44% | -39% | -18% | -37% | -52% | |
| Peers Max Drawdown | -19% | -49% | -30% | -33% | -37% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ZTS, ELAN, MRK, NEOG, IDXX. See PAHC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/24/2026 (YTD)
How Low Can It Go
| Event | PAHC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.3% | -18.8% |
| % Gain to Breakeven | 45.5% | 23.1% |
| Time to Breakeven | 21 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -33.3% | -9.5% |
| % Gain to Breakeven | 49.9% | 10.5% |
| Time to Breakeven | 171 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -17.8% | -6.7% |
| % Gain to Breakeven | 21.7% | 7.1% |
| Time to Breakeven | 333 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -37.2% | -24.5% |
| % Gain to Breakeven | 59.3% | 32.4% |
| Time to Breakeven | 696 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.6% | -33.7% |
| % Gain to Breakeven | 46.2% | 50.9% |
| Time to Breakeven | 43 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -29.5% | -19.2% |
| % Gain to Breakeven | 41.9% | 23.8% |
| Time to Breakeven | 2439 days | 105 days |
In The Past
Phibro Animal Health's stock fell -31.3% during the 2025 US Tariff Shock. Such a loss loss requires a 45.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | PAHC | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.3% | -18.8% |
| % Gain to Breakeven | 45.5% | 23.1% |
| Time to Breakeven | 21 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -33.3% | -9.5% |
| % Gain to Breakeven | 49.9% | 10.5% |
| Time to Breakeven | 171 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -37.2% | -24.5% |
| % Gain to Breakeven | 59.3% | 32.4% |
| Time to Breakeven | 696 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.6% | -33.7% |
| % Gain to Breakeven | 46.2% | 50.9% |
| Time to Breakeven | 43 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -29.5% | -19.2% |
| % Gain to Breakeven | 41.9% | 23.8% |
| Time to Breakeven | 2439 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -34.6% | -12.2% |
| % Gain to Breakeven | 52.9% | 13.9% |
| Time to Breakeven | 461 days | 62 days |
In The Past
Phibro Animal Health's stock fell -31.3% during the 2025 US Tariff Shock. Such a loss loss requires a 45.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Phibro Animal Health (PAHC)
Phibro Animal Health Corporation (PAHC) is a global animal health company that develops, manufactures, and supplies a comprehensive range of products for the livestock industry. Its primary focus is on enhancing the health and performance of food animals such as poultry, swine, beef and dairy cattle, and aquaculture through its Animal Health, Mineral Nutrition, and Performance Products segments.
The company's core offerings in Animal Health include critical solutions like antibacterials, anticoccidials, anthelmintics, and anti-bloat treatments, designed to prevent and treat various diseases in livestock. Phibro also provides nutritional specialty products to improve animal health and performance, alongside vaccines primarily for poultry and swine markets. Complementing this, its Mineral Nutrition segment produces essential trace minerals such as zinc, manganese, copper, and iron. Additionally, through its Performance Products segment, Phibro supplies specialty ingredients to personal care, industrial chemical, and chemical catalyst industries.
Phibro serves a broad global customer base, primarily selling its animal health and mineral nutrition products to integrated poultry, swine, and cattle integrators, as well as commercial animal feed manufacturers, wholesalers, and distributors. The company maintains a significant international presence, operating across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region.
AI Analysis | Feedback
1. Imagine a company like Pfizer or Merck, but entirely dedicated to developing medicines, vaccines, and nutritional supplements for farm animals like chickens, pigs, and cattle.
2. It's like a specialized version of a major pharmaceutical company, providing health and nutrition solutions specifically for livestock.
AI Analysis | Feedback
Major products of Phibro Animal Health (PAHC) include:
- Antibacterials: Biological or chemical products used to treat or prevent bacterial diseases in animals.
- Anticoccidials: Products primarily used to prevent and control coccidiosis in poultry and cattle.
- Anthelmintics: Treatments for infestations of parasitic intestinal worms in animals.
- Anti-bloat Treatment Products: Products designed for cattle to control bloat when grazing.
- Nutritional Specialty Products: Formulations that enhance animal nutrition to improve health and performance.
- Vaccines: Products developed to prevent diseases, primarily for poultry and swine.
- Trace Minerals: Formulations and concentrations of essential minerals like zinc, manganese, copper, and iron for animal health.
- Specialty Ingredients: Various ingredients supplied for use in the personal care, industrial chemical, and chemical catalyst industries.
AI Analysis | Feedback
Phibro Animal Health (PAHC) primarily sells its products to other companies, not individuals. Based on the provided background information, the company's major customers are described by category rather than specific named companies. These categories include:
- Integrated poultry, swine, and cattle integrators
- Commercial animal feed manufacturers
- Wholesalers and distributors of animal health and mineral nutrition products
Specific names of customer companies and their symbols are not provided in the background text.
AI Analysis | Feedback
null
AI Analysis | Feedback
Jack C. Bendheim
Chairman of the Board of Directors, President and Chief Executive Officer (transitioning to Executive Chairman effective July 1, 2026)
Mr. Bendheim joined Phibro in 1969, serving as President since 1988 and as Chief Executive Officer since March 2014, having also held the CEO role from 1998 to 2002. He has been instrumental in guiding the company through significant global expansion, portfolio growth, and operational transformation. Mr. Bendheim was a co-founder of PAHC Holdings Corporation and previously served on the Board of Directors of Empire Resources, Inc. until 2017. He is also a past Chairman of the Animal Health Institute.
Daniel M. Bendheim
Executive Vice President, Corporate Strategy (assuming Chief Executive Officer and President roles effective July 1, 2026)
Mr. Bendheim joined Phibro in 1997. His previous roles include Vice President of Business Development (2001), President of Performance Products (2004), and Executive Vice President, Corporate Strategy (March 2014). Most recently, he served as Chief Transformation Officer for the company’s "Phibro Forward" initiative, focusing on efficiency, growth, and cultural engagement. Daniel M. Bendheim is the son of Jack C. Bendheim.
Glenn C. David
Chief Financial Officer (effective February 9, 2024)
Mr. David joined Phibro in February 2024, bringing over 30 years of commercial and financial leadership experience. Prior to Phibro, he served as Chief Financial Officer of Zoetis Inc. from 2016 to 2021, and also held executive positions there as Group President for International Operations, Aquaculture, Biodevices & Insurance, and US Operations, Diagnostics, Biodevices & Insurance. Before the Zoetis IPO, Mr. David held various financial roles at Pfizer Inc., including Vice President of Global Finance for Pfizer Animal Health.
Larry L. Miller
Chief Operating Officer
Mr. Miller joined Phibro in May 2008 with over 20 years of experience in the animal health industry. His background includes serving as Vice President of Intervet/SPAH global ruminant business at Schering-Plough Corporation from 2004 to 2008, and as Senior Director of U.S. Cattle for Schering-Plough Animal Health. He also held the role of General Manager of Australia-New Zealand Animal Health from 1998 to 2004.
Jonathan Bendheim
Executive Vice President, Global Technology and Talent, Director, President, MACIE Region and General Manager, Israel Operations
Mr. Bendheim serves as a Director of Phibro Animal Health Corporation and holds executive leadership roles overseeing global technology, talent, and regional operations. He is also the son of Jack C. Bendheim.
AI Analysis | Feedback
The key risks to Phibro Animal Health (PAHC) primarily stem from evolving regulatory landscapes, broad macroeconomic pressures, and intense industry competition.
- Regulatory Scrutiny and the Shift Away from Certain Medicament Use: Phibro Animal Health faces significant risks due to increasing global regulations concerning the use of antibiotics and other medicated feed additives in livestock. For instance, the company's product Mecadox (carbadox) has been banned in the European Union since 1998 and in several other countries outside the United States. There is growing regulatory pressure due to concerns over antimicrobial resistance, necessitating substantial investment in compliant solutions and alternative products. Phibro has already voluntarily removed growth promotion claims from its medically important antibiotics in the U.S., where a significant portion of its animal health revenue is generated. Failure to maintain and renew product licenses can result in the loss of marketing rights in various countries. This evolving regulatory environment, coupled with shifting consumer preferences towards alternative proteins, poses a direct threat to parts of Phibro's traditional product portfolio.
- Macroeconomic Headwinds and Geopolitical Instability: The company's business is vulnerable to a range of macroeconomic factors and geopolitical events. These include ongoing military conflicts, such as the armed conflict between Russia and Ukraine, which can lead to economic sanctions, trade bans, and broader disruptions. Changes in U.S. trade policy, including tariffs and revised trade agreements, could create supply-chain inefficiencies and affect the cost and availability of key materials. Phibro also faces inflationary pressures on raw materials and energy, volatility in foreign exchange rates and interest rates, and heightened cybersecurity threats. These external factors can broadly impact the company's operational costs, revenue, and global market access.
- Intense Competition and Market Consolidation: Phibro Animal Health operates in highly competitive industries, facing a substantial and continually evolving number of global and regional competitors. This includes competition from larger, more diversified pharmaceutical companies and specialized animal health firms. The animal health market is also experiencing consolidation, which could favor larger competitors with greater market share and research and development capabilities, potentially limiting Phibro's ability to innovate at the same pace. Phibro's market capitalization is notably smaller than industry leaders, which can impact its competitive positioning.
AI Analysis | Feedback
null
AI Analysis | Feedback
Phibro Animal Health (PAHC) operates in several addressable markets for its animal health, mineral nutrition, and performance products.
Animal Health Products
- The global animal health market was valued at approximately USD 68.7 billion in 2025 and is projected to reach USD 156.0 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 11.0% from 2026 to 2033. Other estimates place the global animal health market at USD 40.1 billion in 2025, projected to reach USD 51.6 billion by 2034 with a CAGR of 2.73% from 2026-2034. Another report valued the global animal health market at USD 73.10 billion in 2025, with a projection to reach USD 172.08 billion by 2035 at a CAGR of 8.94% from 2026 to 2035. North America held the largest share of this market, approximately 36% in 2025.
- The global veterinary therapeutics market was valued at USD 47.25 billion in 2025 and is projected to grow to USD 81.59 billion by 2034, with a CAGR of 6.40% during the forecast period.
- The global livestock pharmaceuticals market was valued at USD 21.1 billion in 2025 and is expected to reach USD 35.7 billion by 2032, growing at a CAGR of 7.8% from 2026-2032.
- The global aquaculture healthcare market was valued at USD 1.35 billion in 2025 and is projected to reach approximately USD 3.04 billion by 2035, growing at a CAGR of 8.46% from 2026 to 2035. Other estimates place the global aquaculture healthcare market size at USD 1.97 billion in 2025, expected to reach USD 3.70 billion by 2033 at a CAGR of 8.22%.
Mineral Nutrition Products
- The global animal nutrition market was valued at USD 26.89 billion in 2025 and is predicted to increase to approximately USD 52.20 billion by 2035, expanding at a CAGR of 6.86% from 2026 to 2035. Asia-Pacific dominated the animal nutrition market, accounting for a 40% share in 2024.
- The global animal feed trace minerals market size is projected to reach approximately USD 7.3 billion by 2031, growing at a 6.5% CAGR over the forecast period, from USD 5.33 billion in 2026. The global animal feed organic trace minerals market size was valued at USD 841.9 million in 2025 and is projected to reach USD 1.5 billion by 2035, reflecting a 5.9% CAGR from 2026 to 2035.
Performance Products
- The global personal care specialty ingredients market was estimated at USD 13.65 billion in 2024 and is projected to reach USD 22.80 billion by 2033, growing at a CAGR of 5.87% from 2025 to 2033. Other sources indicate the market was valued at USD 13.49 billion in 2023 and is expected to reach USD 24.51 billion by 2033, at a CAGR of 6.15%.
- The global chemical catalyst market was valued at USD 42.85 billion in 2024 and is predicted to reach USD 67.19 billion by 2034, exhibiting a CAGR of 4.60% between 2025 and 2034. Another report estimates the global catalyst market size at USD 43.0 billion in 2025, projected to reach USD 59.1 billion by 2034 with a CAGR of 3.60% during 2026-2034.
- The global chemicals market was valued at USD 5.82 trillion in 2024 and is expected to reach USD 7.85 trillion by 2032, growing at a CAGR of 3.81% from 2025-2032. Specialty chemicals, a segment within the broader chemical market, held approximately 22% of the global chemical market share in 2024.
AI Analysis | Feedback
Phibro Animal Health (PAHC) is poised for future revenue growth over the next two to three years, driven by several key factors:
- Successful Integration and Expansion of the Acquired Medicated Feed Additives (MFA) Portfolio: The acquisition of the Zoetis MFA portfolio has been a significant driver of growth. This integration has consistently contributed to substantial increases in MFA sales, playing a crucial role in the Animal Health segment's strong performance. The new MFA business contributed $208.2 million in sales in fiscal year 2025 and drove an 81% total MFA and other growth in Q1 FY2026.
- Robust Demand and Growth within the Animal Health Segment (Vaccines and Nutritional Specialties): Beyond the acquired MFA portfolio, Phibro's core Animal Health segment is experiencing healthy growth in other key product areas. Vaccine net sales have seen increases driven by poultry product introductions in Latin America and rising domestic and international demand. Nutritional Specialties are also contributing positively, particularly due to increased domestic demand for dairy products and higher sales of microbial and companion animal products. Expanding capacity and sustained global demand are expected to make the vaccines business a key growth driver.
- Strong Underlying Demand in Global Protein Markets: Management commentary consistently highlights resilient protein markets across poultry, swine, beef, dairy, and aquaculture as a fundamental support for the demand for Phibro's animal health and nutrition products. Favorable market conditions in these sectors are expected to continue driving the need for the company's offerings.
- New Product Launches and Innovation: Phibro is demonstrating its ability to develop and commercialize new offerings. The exceptional growth in the "Z-Product" line showcases the company's innovation strategy. Additionally, recent initiatives such as a licensing agreement for canine periodontal care and the nationwide rollout of Restoris piezoelectric dental gel signal ongoing new product introductions that are expected to contribute to future revenue.
AI Analysis | Feedback
Outbound Investments
- Phibro Animal Health acquired Zoetis' medicated feed additive (MFA) portfolio and water-soluble products for $350 million in October 2024. This acquisition included over 37 product lines and six manufacturing facilities, and the acquired portfolio generated approximately $400 million in revenue in 2023.
- The company has made significant investments to expand vaccine manufacturing capacity at several locations, including a new vaccine production facility in Guarulhos, Brazil.
- Phibro is actively investing in expanding its companion animal business and pipeline.
Capital Expenditures
- Phibro's projected capital expenditures for fiscal year 2026 are $60 million.
- The company reported $46 million in capital expenditures for the second quarter of fiscal year 2026 (ended December 2025).
- For the first quarter of fiscal year 2026 (ended September 2025), capital expenditures were $43 million.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 54.69 |
| Mkt Cap | 22.1 |
| Rev LTM | 4,670 |
| Op Inc LTM | 853 |
| FCF LTM | 692 |
| FCF 3Y Avg | 609 |
| CFO LTM | 894 |
| CFO 3Y Avg | 772 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.7% |
| Rev Chg 3Y Avg | 6.5% |
| Rev Chg Q | 7.6% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 13.8% |
| Op Inc Chg 3Y Avg | 11.4% |
| Op Mgn LTM | 15.9% |
| Op Mgn 3Y Avg | 14.2% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 19.5% |
| CFO/Rev 3Y Avg | 18.3% |
| FCF/Rev LTM | 13.9% |
| FCF/Rev 3Y Avg | 14.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Animal Health | 963 | 706 | 660 | 607 | 546 |
| Mineral Nutrition | 253 | 244 | 243 | 260 | 221 |
| Performance Products | 80 | 68 | 75 | 76 | 67 |
| Total | 1,296 | 1,018 | 978 | 942 | 833 |
| $ Mil | 2025 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Animal Health | 182 | 108 | 97 | 98 | 97 |
| Mineral Nutrition | 19 | 15 | 21 | 14 | 12 |
| Performance Products | 9 | 8 | 7 | 8 | 3 |
| Insurance proceeds | 3 | ||||
| Stock-based compensation expense | -1 | 0 | -1 | -2 | |
| Depreciation and amortization - Corporate | -2 | -2 | -2 | -2 | -2 |
| Phibro Forward income growth initiatives implementation costs - cost of goods sold | -4 | ||||
| Acquisition-related cost of goods sold | -6 | 0 | -0 | -0 | |
| Phibro Forward income growth initiatives implementation costs - Selling, general and administrative | -7 | ||||
| Acquisition-related transaction costs | -13 | 0 | -0 | -0 | |
| Corporate costs | -70 | -50 | -46 | -43 | -40 |
| Environmental remediation costs | -7 | ||||
| Gain on sale of investment | 0 | 1 | |||
| Acquisition-related other | 3 | ||||
| Restructuring costs | -0 | ||||
| Total | 110 | 72 | 79 | 75 | 69 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Animal Health | 684 | 699 | 655 | 595 | 561 |
| Corporate | 180 | 147 | 150 | 142 | 127 |
| Mineral Nutrition | 67 | 76 | 87 | 67 | 66 |
| Performance Products | 51 | 50 | 39 | 37 | 31 |
| Total | 982 | 971 | 932 | 841 | 784 |
Price Behavior
Price Behavior
| Market Price | $34.03 | |
| Market Cap ($ Bil) | 1.4 | |
| First Trading Date | 04/11/2014 | |
| Distance from 52W High | -42.6% | |
| 50 Days | 200 Days | |
| DMA Price | $32.56 | $42.42 |
| DMA Trend | down | down |
| Distance from DMA | 4.5% | -19.8% |
| 3M | 1YR | |
| Volatility | 72.9% | 58.4% |
| Downside Capture | 238.39 | 108.87 |
| Upside Capture | -24.84 | 106.82 |
| Correlation (SPY) | 18.0% | 23.9% |
PAHC Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.73 | 1.07 | 1.43 | 1.03 | 1.09 | 1.09 |
| Up Beta | 1.39 | 2.41 | 2.11 | 2.22 | 1.88 | 0.99 |
| Down Beta | 2.43 | 0.26 | 0.25 | 0.35 | 0.48 | 0.89 |
| Up Capture | 16% | -76% | -5% | 56% | 111% | 235% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 10 | 16 | 27 | 58 | 119 | 369 |
| Down Capture | -11% | 270% | 300% | 118% | 105% | 105% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 11 | 25 | 36 | 67 | 133 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PAHC | |
|---|---|---|---|---|
| PAHC | 15.8% | 58.3% | 0.47 | - |
| Sector ETF (XLV) | 20.9% | 15.7% | 1.02 | 26.6% |
| Equity (SPY) | 17.6% | 12.7% | 1.00 | 23.9% |
| Gold (GLD) | 19.2% | 28.1% | 0.61 | 3.5% |
| Commodities (DBC) | 34.7% | 19.1% | 1.42 | -19.6% |
| Real Estate (VNQ) | 13.8% | 14.1% | 0.69 | 26.6% |
| Bitcoin (BTCUSD) | -45.4% | 42.9% | -1.29 | 3.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PAHC | |
|---|---|---|---|---|
| PAHC | 9.2% | 47.1% | 0.34 | - |
| Sector ETF (XLV) | 6.4% | 15.0% | 0.25 | 30.8% |
| Equity (SPY) | 12.8% | 17.1% | 0.58 | 32.6% |
| Gold (GLD) | 17.0% | 18.4% | 0.75 | 1.3% |
| Commodities (DBC) | 9.6% | 19.5% | 0.38 | 1.3% |
| Real Estate (VNQ) | 3.0% | 18.9% | 0.06 | 33.4% |
| Bitcoin (BTCUSD) | 15.7% | 53.4% | 0.47 | 14.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PAHC | |
|---|---|---|---|---|
| PAHC | 7.4% | 44.6% | 0.32 | - |
| Sector ETF (XLV) | 10.0% | 16.6% | 0.49 | 36.1% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 37.6% |
| Gold (GLD) | 11.3% | 16.1% | 0.57 | 1.4% |
| Commodities (DBC) | 7.2% | 17.9% | 0.32 | 7.5% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.21 | 34.6% |
| Bitcoin (BTCUSD) | 58.3% | 66.2% | 0.98 | 13.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/9/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | -26.2% | -39.7% | -44.3% |
| 2/4/2026 | 22.0% | 25.7% | 17.1% |
| 11/5/2025 | 4.6% | 10.1% | -2.3% |
| 8/27/2025 | 19.4% | 21.7% | 20.9% |
| 5/7/2025 | 14.7% | 20.5% | 24.8% |
| 2/5/2025 | 9.9% | 10.0% | 6.2% |
| 11/6/2024 | 1.8% | 9.4% | 1.0% |
| 8/28/2024 | 3.2% | -6.1% | 6.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 16 | 16 | 12 |
| # Negative | 8 | 8 | 12 |
| Median Positive | 4.4% | 9.3% | 7.5% |
| Median Negative | -7.1% | -11.9% | -9.4% |
| Max Positive | 22.0% | 25.7% | 24.8% |
| Max Negative | -26.2% | -39.7% | -44.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/6/2026 | -26.2% | -39.7% | -44.3% |
| 2/4/2026 | 22.0% | 25.7% | 17.1% |
| 11/5/2025 | 4.6% | 10.1% | -2.3% |
| 8/27/2025 | 19.4% | 21.7% | 20.9% |
| 5/7/2025 | 14.7% | 20.5% | 24.8% |
| 2/5/2025 | 9.9% | 10.0% | 6.2% |
| 11/6/2024 | 1.8% | 9.4% | 1.0% |
| 8/28/2024 | 3.2% | -6.1% | 6.7% |
| 5/8/2024 | 3.0% | 6.2% | 0.6% |
| 2/7/2024 | 7.4% | 12.0% | 21.9% |
| 11/8/2023 | -18.5% | -12.8% | -6.9% |
| 8/30/2023 | -5.9% | -15.1% | -13.2% |
| 5/3/2023 | -8.3% | -9.7% | -11.9% |
| 2/8/2023 | 0.0% | 2.5% | -3.1% |
| 11/9/2022 | -3.1% | -11.0% | -11.1% |
| 8/24/2022 | -5.6% | -14.8% | -24.5% |
| 5/4/2022 | -9.1% | -9.3% | -5.2% |
| 2/9/2022 | 7.0% | 17.1% | 8.0% |
| 11/2/2021 | 4.1% | 4.0% | -5.2% |
| 8/25/2021 | -2.9% | 3.8% | -7.7% |
| 5/6/2021 | 6.3% | 4.6% | 13.8% |
| 2/3/2021 | 2.9% | 4.2% | 3.6% |
| 11/4/2020 | 0.9% | 9.2% | 6.9% |
| 8/26/2020 | 1.7% | 1.6% | -11.8% |
| SUMMARY STATS | |||
| # Positive | 16 | 16 | 12 |
| # Negative | 8 | 8 | 12 |
| Median Positive | 4.4% | 9.3% | 7.5% |
| Median Negative | -7.1% | -11.9% | -9.4% |
| Max Positive | 22.0% | 25.7% | 24.8% |
| Max Negative | -26.2% | -39.7% | -44.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/04/2026 | 10-Q |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/27/2025 | 10-K |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/05/2025 | 10-Q |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/28/2024 | 10-K |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/07/2024 | 10-Q |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/30/2023 | 10-K |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/08/2023 | 10-Q |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/24/2022 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/06/2026 | 10-Q |
| 12/31/2025 | 02/04/2026 | 10-Q |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/27/2025 | 10-K |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/05/2025 | 10-Q |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/28/2024 | 10-K |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/07/2024 | 10-Q |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/30/2023 | 10-K |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/08/2023 | 10-Q |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/24/2022 | 10-K |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/09/2022 | 10-Q |
| 09/30/2021 | 11/02/2021 | 10-Q |
| 06/30/2021 | 08/25/2021 | 10-K |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/03/2021 | 10-Q |
| 09/30/2020 | 11/04/2020 | 10-Q |
| 06/30/2020 | 08/26/2020 | 10-K |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 02/03/2020 | 10-Q |
| 09/30/2019 | 11/04/2019 | 10-Q |
| 06/30/2019 | 08/27/2019 | 10-K |
Recent Forward Guidance
Updated 7/12/2026Latest: Q3 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net sales | 1.46 Bil | 1.48 Bil | 1.50 Bil | 0.3% | Raised | Guidance: 1.48 Bil for 2026 | |
| 2026 Net income | 92.00 Mil | 96.00 Mil | 100.00 Mil | 6.7% | Raised | Guidance: 90.00 Mil for 2026 | |
| 2026 Diluted EPS | 2.25 | 2.35 | 2.44 | 6.6% | Raised | Guidance: 2.2 for 2026 | |
| 2026 Adjusted EBITDA | 247.00 Mil | 251.00 Mil | 255.00 Mil | 0.4% | Raised | Guidance: 250.00 Mil for 2026 | |
| 2026 Adjusted net income | 122.00 Mil | 124.50 Mil | 127.00 Mil | 0.8% | Raised | Guidance: 123.50 Mil for 2026 | |
| 2026 Adjusted diluted EPS | 2.98 | 3.04 | 3.1 | 0.8% | Raised | Guidance: 3.02 for 2026 | |
| 2026 Adjusted effective tax rate | 25.0% | 0.0% | Affirmed | Guidance: 25.0% for 2026 | |||
Prior: Q2 2026 Earnings Reported 2/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net sales | 1.45 Bil | 1.48 Bil | 1.50 Bil | 1.4% | Raised | Guidance: 1.46 Bil for 2026 | |
| 2026 Net income | 85.00 Mil | 90.00 Mil | 95.00 Mil | 12.5% | Raised | Guidance: 80.00 Mil for 2026 | |
| 2026 Diluted EPS | 2.08 | 2.2 | 2.32 | 12.5% | Raised | Guidance: 1.96 for 2026 | |
| 2026 Adjusted EBITDA | 245.00 Mil | 250.00 Mil | 255.00 Mil | 6.4% | Raised | Guidance: 235.00 Mil for 2026 | |
| 2026 Adjusted net income | 120.00 Mil | 123.50 Mil | 127.00 Mil | 10.8% | Raised | Guidance: 111.50 Mil for 2026 | |
| 2026 Adjusted diluted EPS | 2.93 | 3.02 | 3.1 | 10.6% | Raised | Guidance: 2.73 for 2026 | |
| 2026 Adjusted effective tax rate | 25.0% | 0.0% | Affirmed | Guidance: 25.0% for 2026 | |||
Q1 2026 Earnings Reported 11/5/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Net sales | 1.43 Bil | 1.46 Bil | 1.48 Bil | 0 | Affirmed | Guidance: 1.46 Bil for 2026 | |
| 2026 Net income | 75.00 Mil | 80.00 Mil | 85.00 Mil | 2.6% | Raised | Guidance: 78.00 Mil for 2026 | |
| 2026 Diluted EPS | 1.83 | 1.96 | 2.08 | 2.4% | Raised | Guidance: 1.91 for 2026 | |
| 2026 Adjusted EBITDA | 230.00 Mil | 235.00 Mil | 240.00 Mil | 2.2% | Raised | Guidance: 230.00 Mil for 2026 | |
| 2026 Adjusted net income | 108.00 Mil | 111.50 Mil | 115.00 Mil | 4.7% | Raised | Guidance: 106.50 Mil for 2026 | |
| 2026 Adjusted diluted EPS | 2.64 | 2.73 | 2.81 | 4.4% | Raised | Guidance: 2.61 for 2026 | |
| 2026 Adjusted effective income tax rate | 25.0% | 0 | Affirmed | Guidance: 25.0% for 2026 | |||
Insider Activity
Updated 7/2/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Corcoran, E Thomas | Direct | Buy | 6022026 | 31.77 | 10,000 | 317,700 | 1,317,152 | Form | |
| 2 | Bendheim, Jack | President and CEO | See | Sell | 5072026 | 48.49 | 4,528 | 219,568 | 2,722,874 | Form |
| 3 | Bendheim, Jack | President and CEO | See | Sell | 5072026 | 57.37 | 7,040 | 403,850 | 3,480,910 | Form |
| 4 | Bendheim, Jack | President and CEO | See | Sell | 5072026 | 55.80 | 7,040 | 392,810 | 3,778,565 | Form |
| 5 | Bendheim, Jack | President and CEO | See | Sell | 4302026 | 52.76 | 7,040 | 371,465 | 3,944,707 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Corcoran, E Thomas | Direct | Buy | 6022026 | 31.77 | 10,000 | 317,700 | 1,317,152 | Form | |
| 2 | Bendheim, Jack | President and CEO | See | Sell | 5072026 | 48.49 | 4,528 | 219,568 | 2,722,874 | Form |
| 3 | Bendheim, Jack | President and CEO | See | Sell | 5072026 | 57.37 | 7,040 | 403,850 | 3,480,910 | Form |
| 4 | Bendheim, Jack | President and CEO | See | Sell | 5072026 | 55.80 | 7,040 | 392,810 | 3,778,565 | Form |
| 5 | Bendheim, Jack | President and CEO | See | Sell | 4302026 | 52.76 | 7,040 | 371,465 | 3,944,707 | Form |
| 6 | Bendheim, Jack | President and CEO | See | Sell | 4302026 | 52.92 | 7,040 | 372,553 | 4,328,808 | Form |
| 7 | Bendheim, Jack | President and CEO | See | Sell | 4302026 | 55.91 | 7,040 | 393,575 | 4,966,647 | Form |
| 8 | Bendheim, Jack | President and CEO | See | Sell | 4232026 | 54.09 | 7,040 | 380,826 | 5,186,589 | Form |
| 9 | Bendheim, Jack | President and CEO | See | Sell | 4232026 | 54.29 | 7,040 | 382,185 | 5,587,280 | Form |
| 10 | Bendheim, Jack | President and CEO | See | Sell | 4232026 | 55.98 | 7,040 | 394,081 | 6,155,271 | Form |
| 11 | Bendheim, Jack | President and CEO | See | Sell | 4162026 | 54.64 | 7,040 | 384,662 | 6,392,819 | Form |
| 12 | Bendheim, Jack | President and CEO | See | Sell | 4162026 | 56.96 | 7,040 | 401,011 | 1,369,362 | Form |
| 13 | Bendheim, Jack | President and CEO | See | Sell | 4162026 | 59.08 | 7,040 | 415,922 | 1,836,201 | Form |
| 14 | Bendheim, Jack | President and CEO | See | Sell | 3312026 | 53.90 | 7,040 | 379,428 | 2,054,516 | Form |
| 15 | Bendheim, Jack | President and CEO | See | Sell | 3312026 | 53.61 | 7,040 | 377,406 | 2,420,972 | Form |
| 16 | Bendheim, Jack | President and CEO | See | Sell | 3262026 | 56.80 | 7,040 | 399,876 | 2,964,987 | Form |
| 17 | Bendheim, Jack | President and CEO | See | Sell | 3262026 | 55.91 | 7,040 | 393,606 | 3,312,102 | Form |
| 18 | Bendheim, Jack | President and CEO | See | Sell | 3262026 | 52.93 | 7,040 | 372,623 | 3,508,164 | Form |
| 19 | Bendheim, Jack | President and CEO | See | Sell | 3192026 | 52.52 | 7,040 | 369,729 | 3,850,644 | Form |
| 20 | Bendheim, Jack | President and CEO | See | Sell | 3192026 | 52.68 | 10,560 | 556,330 | 4,233,584 | Form |
| 21 | Bendheim, Jack | President and CEO | See | Sell | 3192026 | 51.66 | 5,280 | 272,760 | 4,696,836 | Form |
| 22 | Bendheim, Jack | President and CEO | See | Sell | 3162026 | 48.91 | 5,280 | 258,245 | 4,705,142 | Form |
| 23 | Bendheim, Jack | President and CEO | See | Sell | 2262026 | 53.73 | 7,040 | 378,266 | 79,522 | Form |
| 24 | Bendheim, Jack | President and CEO | See | Sell | 2262026 | 51.71 | 7,040 | 364,041 | 440,573 | Form |
| 25 | Bendheim, Jack | President and CEO | See | Sell | 2262026 | 51.37 | 7,040 | 361,630 | 799,285 | Form |
| 26 | Bendheim, Jack | President and CEO | See | Sell | 2232026 | 51.42 | 7,040 | 361,967 | 1,161,997 | Form |
| 27 | Bendheim, Jack | President and CEO | See | Sell | 2232026 | 50.26 | 7,040 | 353,808 | 1,489,612 | Form |
| 28 | Bendheim, Jack | President and CEO | See | Sell | 2182026 | 51.40 | 7,040 | 361,825 | 1,885,189 | Form |
| 29 | Bendheim, Jack | President and CEO | See | Sell | 2182026 | 51.96 | 7,040 | 365,822 | 2,271,835 | Form |
| 30 | Bendheim, Jack | President and CEO | See | Sell | 2112026 | 51.62 | 14,184 | 732,186 | 2,620,259 | Form |
| 31 | Bendheim, Jack | President and CEO | See | Sell | 2112026 | 51.81 | 58,014 | 3,005,525 | 3,364,547 | Form |
| 32 | Bendheim, Jack | President and CEO | See | Sell | 2092026 | 48.38 | 110,842 | 5,362,103 | 5,948,228 | Form |
| 33 | Bendheim, Jack | President and CEO | See | Sell | 2052026 | 41.15 | 3,520 | 144,863 | 2,008,335 | Form |
| 34 | Bendheim, Jack | President and CEO | See | Sell | 2052026 | 41.47 | 9,660 | 400,610 | 925,632 | Form |
| 35 | Bendheim, Jack | President and CEO | See | Sell | 2022026 | 40.09 | 6,693 | 268,350 | 1,282,209 | Form |
| 36 | Bendheim, Jack | President and CEO | See | Sell | 2022026 | 40.12 | 6,772 | 271,687 | 1,551,530 | Form |
| 37 | Bendheim, Jack | President and CEO | See | Sell | 1272026 | 40.55 | 1,235 | 50,084 | 626,353 | Form |
| 38 | Bendheim, Jack | President and CEO | See | Sell | 1222026 | 41.98 | 13,158 | 552,420 | 754 | Form |
| 39 | Bendheim, Jack | President and CEO | See | Sell | 1222026 | 41.68 | 14,687 | 612,128 | 1,243,594 | Form |
| 40 | Bendheim, Jack | President and CEO | See | Sell | 1132026 | 40.16 | 213 | 8,554 | 1,552,545 | Form |
| 41 | Bendheim, Jack | President and CEO | See | Sell | 12152025 | 40.93 | 5,752 | 235,405 | 1,604,288 | Form |
| 42 | Bendheim, Jack | President and CEO | See | Sell | 12102025 | 40.19 | 1,288 | 51,763 | 1,806,571 | Form |
| 43 | Bendheim, Jack | President and CEO | See | Sell | 12102025 | 40.06 | 3,520 | 141,018 | 1,852,458 | Form |
| 44 | Bendheim, Jack | President and CEO | See | Sell | 12042025 | 41.22 | 3,520 | 145,096 | 2,051,128 | Form |
| 45 | Bendheim, Jack | President and CEO | See | Sell | 12042025 | 40.77 | 3,520 | 143,511 | 2,172,231 | Form |
| 46 | Bendheim, Jack | President and CEO | See | Sell | 12022025 | 41.66 | 3,520 | 146,636 | 1,116,434 | Form |
| 47 | Bendheim, Jack | President and CEO | See | Sell | 12022025 | 42.54 | 3,520 | 149,740 | 1,289,807 | Form |
| 48 | Bendheim, Jack | President and CEO | See | Sell | 11262025 | 44.02 | 5,280 | 232,434 | 1,489,691 | Form |
| 49 | Bendheim, Jack | President and CEO | See | Sell | 11262025 | 43.93 | 7,040 | 309,240 | 1,718,389 | Form |
| 50 | Bendheim, Jack | President and CEO | See | Sell | 11242025 | 41.76 | 3,520 | 147,002 | 1,927,727 | Form |
| 51 | Bendheim, Jack | President and CEO | See | Sell | 11182025 | 43.82 | 5,280 | 231,377 | 2,177,044 | Form |
| 52 | Bendheim, Jack | President and CEO | See | Sell | 11182025 | 44.56 | 5,280 | 235,254 | 2,448,781 | Form |
| 53 | Bendheim, Jack | President and CEO | See | Sell | 11132025 | 44.47 | 8,801 | 391,417 | 233,045 | Form |
| 54 | Bendheim, Jack | President and CEO | See | Sell | 11132025 | 45.23 | 21,536 | 973,976 | 635,011 | Form |
| 55 | Bendheim, Jack | President and CEO | See | Sell | 11102025 | 45.29 | 38,303 | 1,734,767 | 931,945 | Form |
| 56 | Bendheim, Jack | President and CEO | See | Sell | 11102025 | 42.86 | 3,520 | 150,851 | 2,523,326 | Form |
| 57 | Bendheim, Jack | President and CEO | See | Sell | 11062025 | 41.21 | 3,520 | 145,075 | 2,571,783 | Form |
| 58 | Bendheim, Jack | President and CEO | See | Sell | 11062025 | 43.10 | 3,520 | 151,703 | 2,840,991 | Form |
| 59 | Bendheim, Jack | President and CEO | See | Sell | 10302025 | 41.07 | 3,520 | 144,582 | 1,825,351 | Form |
| 60 | Bendheim, Jack | President and CEO | See | Sell | 10302025 | 41.66 | 3,520 | 146,627 | 1,997,793 | Form |
| 61 | Bendheim, Jack | President and CEO | See | Sell | 10302025 | 41.56 | 3,520 | 146,277 | 2,139,308 | Form |
| 62 | Bendheim, Jack | President and CEO | See | Sell | 10242025 | 41.75 | 3,520 | 146,956 | 2,296,195 | Form |
| 63 | Bendheim, Jack | President and CEO | See | Sell | 10242025 | 40.18 | 3,520 | 141,432 | 2,351,310 | Form |
| 64 | Bendheim, Jack | President and CEO | See | Sell | 10242025 | 40.27 | 11,859 | 477,552 | 2,498,301 | Form |
| 65 | Bendheim, Jack | President and CEO | See | Sell | 10212025 | 40.38 | 16,075 | 649,176 | 965,142 | Form |
| 66 | Bendheim, Jack | President and CEO | See | Sell | 10212025 | 40.03 | 700 | 28,022 | 1,600,235 | Form |
| 67 | Bendheim, Jack | President and CEO | See | Sell | 10012025 | 40.38 | 20,664 | 834,412 | 1,642,416 | Form |
| 68 | Bendheim, Jack | President and CEO | See | Sell | 9222025 | 40.26 | 7,022 | 282,732 | 1,261,784 | Form |
| 69 | Bendheim, Jack | President and CEO | See | Sell | 9112025 | 40.95 | 3,520 | 144,137 | 1,570,765 | Form |
| 70 | Bendheim, Jack | President and CEO | See | Sell | 9112025 | 41.29 | 3,520 | 145,336 | 1,729,162 | Form |
| 71 | Bendheim, Jack | President and CEO | See | Sell | 9112025 | 40.33 | 14,080 | 567,841 | 1,830,964 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/24/2026